Stay updated on Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.

Latest updates to the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe page shows a minor revision update (Revision: v3.4.2 added; Revision: v3.4.1 removed) and no changes to study details or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this is a minor site maintenance update that does not affect study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedMinor version update from v3.3.3 to v3.3.4 with no changes to study content, eligibility criteria, or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations section updated to include Pennsylvania as a site, replacing the prior 'Pennsylvania Locations' entry. The revision tag was updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check91 days agoChange DetectedRevision: v3.3.2 added and v3.2.0 removed, indicating a minor metadata/version update in the page revision history with no impact on content or user-facing functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedRemoved the generic government funding lapse notice that warned about potential data delays and NIH operating status. This note did not pertain to the study data itself. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.